Table 3.

Best overall response and survival outcomes for patients retreated with their original randomized regimen (per-protocol retreatment population; N = 32)

Patients
Ipi + gp100 (n = 23)Ipi + placebo (n = 8)gp100 + placebo (n = 1)
n (%)n (%)n (%)
Best overall response during retreatmenta
 CR0 (0)1 (12.5)0 (0)
 PR3 (13.0)2 (25.0)0 (0)
 SD12 (52.2)3 (37.5)0 (0)
 PD8 (34.8)2 (25.0)1 (100.0)
No. alive >2 y from randomization15 (65.2)4 (50.0)1 (100.0)
Survival range, mo26.0–54.1+24.6–55.1+25.3

Abbreviation: Ipi, ipilimumab 3 mg/kg intravenously every 3 weeks for up to 4 doses.

  • aMeasured by modified World Health Organization criteria.